- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
INmune Bio Inc (INMB)
INmune Bio Inc stock price live, this page displays NASDAQ INMB stock exchange data. View the INMB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the INmune Bio Inc real time stock price chart below.
What Is the INmune Bio Inc Stock Price Today?
The INmune Bio Inc stock price today is 1.38.
What Is the Stock Symbol for INmune Bio Inc?
The stock symbol for INmune Bio Inc is "INMB."
What Stock Exchange Does INmune Bio Inc Trade On?
INmune Bio Inc is listed and trades on the NASDAQ stock exchange.
Is INmune Bio Inc a Good Stock to Buy?
Determining whether INmune Bio Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INMB quote. (ISIN: US45782T1051) Test %CURRENT_YEAR% | %DIVIDEND_YIELD% | %UPSIDE_OR_DOWNSIDE%
What Is the INmune Bio Inc Stock Price Today?
The INmune Bio Inc stock price today is 1.38.
What Is the Stock Symbol for INmune Bio Inc?
The stock symbol for INmune Bio Inc is "INMB."
What Stock Exchange Does INmune Bio Inc Trade On?
INmune Bio Inc is listed and trades on the NASDAQ stock exchange.
Is INmune Bio Inc a Good Stock to Buy?
Determining whether INmune Bio Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INMB quote. (ISIN: US45782T1051) Test %CURRENT_YEAR% | %DIVIDEND_YIELD% | %UPSIDE_OR_DOWNSIDE%
Fair Value
An estimate of a INmune Bio's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.35
1.43
52 wk Range
1.09
11.64
Earnings results expected in 12 days
1/2
Fair Value
An estimate of a INmune Bio's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.351.43
52 wk Range
1.0911.64
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
INMB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a INmune Bio's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
7.00
Upside
+407.25%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer’s disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INmune Bio Inc Earnings Call Summary for Q4/2025
- INmune Bio reported Q4 2025 net loss of $45.9M, up 9% YoY, while R&D expenses dropped 37.7% due to reduced Alzheimer's trial costs.
- Company raised $27.5M in capital through direct and ATM offerings, extending operational runway into Q1 2027 amid continued cash burn.
- CORDStrom platform shows promising progress; regulatory filings planned for U.K., EU, and U.S. in 2026 with potential approvals in 2027.
- Stock rose 4.46% to $1.17 in aftermarket trading despite being down 85% over past year, trading near 52-week low of $1.12.
- FDA provided positive feedback on XPro Alzheimer's program; company maintains capital-efficient strategy focused on data-driven milestones.
Last Updated: 30/03/2026, 22:10
Read Full TranscriptCompare INMB to Peers and Sector
Metrics to compare | INMB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINMBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.8x | −2.5x | −0.4x | |
PEG Ratio | −0.07 | 0.03 | 0.00 | |
Price/Book | 1.6x | 2.5x | 2.6x | |
Price / LTM Sales | 733.8x | 12.7x | 3.2x | |
Upside (Analyst Target) | - | 158.6% | 46.7% | |
Fair Value Upside | Unlock | 17.6% | 7.6% | Unlock |
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.00
(+407.25% Upside)
Earnings
Latest Release
Mar 30, 2026
EPS / Forecast
-0.20 / -0.24
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the INmune Bio (INMB) Stock Price Today?
The INmune Bio stock price today is 1.38 USD.
What Stock Exchange Does INmune Bio Trade On?
INmune Bio is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for INmune Bio?
The stock symbol for INmune Bio is "INMB."
What Is the INmune Bio Market Cap?
As of today, INmune Bio market cap is 36.69M USD.
What Is INmune Bio's Earnings Per Share (TTM)?
The INmune Bio EPS (TTM) is -1.86.
When Is the Next INmune Bio Earnings Date?
INmune Bio will release its next earnings report on May 06, 2026.
From a Technical Analysis Perspective, Is INMB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has INmune Bio Stock Split?
INmune Bio has split 0 times.
How Many Employees Does INmune Bio Have?
INmune Bio has 21 employees.
What is the current trading status of INmune Bio (INMB)?
As of Apr 24, 2026, INmune Bio (INMB) is trading at a price of 1.38 USD, with a previous close of 1.38 USD. The stock has fluctuated within a day range of 1.35 USD to 1.43 USD, while its 52-week range spans from 1.09 USD to 11.64 USD.
What Is INmune Bio (INMB) Price Target According to Analysts?
The average 12-month price target for INmune Bio is 7.00 USD, with a high estimate of 9 USD and a low estimate of 4 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +407.25% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.